/ Not yet recruiting临床1/2期 An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
A Phase I Trial to Evaluate the Tolerability, Pharmacokinetics and Preliminary Efficacy of XS-04 in Patients with Hematologic Malignancies
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
100 项与 NovaOnco Therapeutics Co., Ltd. 相关的临床结果
0 项与 NovaOnco Therapeutics Co., Ltd. 相关的专利（医药）
100 项与 NovaOnco Therapeutics Co., Ltd. 相关的药物交易
100 项与 NovaOnco Therapeutics Co., Ltd. 相关的转化医学
